One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Traditional blood glucose–lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with exenatide have suggested sustained improvements in β-cell function. We investigated the effects of 52 weeks of treatment with exenatide or insulin glargine followed by an off-drug period on hyperglycemic clamp–derived measures of β-cell function, glycemic control, and body weight. RESEARCH DESIGN AND METHODS: Sixty-nine metformin-treated patients with type 2 diabetes were randomly assigned to exenatide (n = 36) or insulin glargine (n = 33). β-Cell function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week 52, and after a 4-week off-drug period. Additional end points included effects on glycemic control, body weight, and safety. RESULTS: Treatment-induced change in combined glucose- and arginine-stimulated C-peptide secretion was 2.46-fold (95% CI 2.09–2.90, P < 0.0001) greater after a 52-week exenatide treatment compared with insulin glargine treatment. Both exenatide and insulin glargine reduced A1C similarly: −0.8 ± 0.1 and −0.7 ± 0.2%, respectively (P = 0.55). Exenatide reduced body weight compared with insulin glargine (difference −4.6 kg, P < 0.0001). β-Cell function measures returned to pretreatment values in both groups after a 4-week off-drug period. A1C and body weight rose to pretreatment values 12 weeks after discontinuation of either exenatide or insulin glargine therapy. CONCLUSIONS: Exenatide significantly improves β-cell function during 1 year of treatment compared with titrated insulin glargine. After cessation of both exenatide and insulin glargine therapy, β-cell function and glycemic control returned to pretreatment values, suggesting that ongoing treatment is necessary to maintain the beneficial effects of either therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 2×
“Obviously, patients treated with exenatide showed a greater improvement in acute -cell function, which is considered to be the result of binding to the -cell GLP-1 receptor (13).”
BackgroundResultKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166 · cited 2×
“3 ype 2 diabetes mellitus is characterized by beta-cell dysfunction against a background of obesity-related insulin resistance (1).”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 4×
“These studies also showed amelioration of surrogate measures of beta-cell function (4-6; 8).”
BackgroundResultInfluentialBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citationCauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
Cited by
Items 301–388 of 388
Jung, S., Nguyen, N.-T. T., Lee, S. A., Seo, S. H., Choi, E., Lee, H. W., Seong, G. H., Bae, O. N., & Lee, E. K. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.06.304 · Cited by 7
Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function
Welters, A., & Lammert, E. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_474 · Cited by 5
O’Connor, R. M. (2026) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2026.1805953 · Cited by 6
“While exenatide provides clinically meaningful glycemic control, its impact on weight loss is relatively modest compared to more recent GLP-1R agents, resulting in less than 3 kg of weight reduction over a 30-week period (DeFronzo et al., 2005; Bunck et al., 2009).”
Esposito, K., Maiorino, M. I., Bellastella, G., Chiodini, P., & Giugliano, D. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0134 · Cited by 4
Effects of exenatide in poorly controlled type 2 diabetes*
Kaimal, N., Schofield, J. D., Zaki, A. A., Patel, R., Sharma, M., Mccourt, E., & Imtiaz, K. E. (2011) · QJM · doi:10.1093/qjmed/hcr180 · Cited by 4
Hong, K.-F., Liu, P., Zhang, W., Gui, D., & Xu, Y. (2023) · Journal of Integrative and Complementary Medicine · doi:10.1089/jicm.2022.0767 · Cited by 6
Incretin therapy for type 2 diabetes mellitus
Klonoff, D. C. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0077-7 · Cited by 4
Su, K., Lv, C., Ji, Z., Wang, Y., Wang, H., Bai, Y., & Liu, Y. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000431 · Cited by 5
Grandy, S., & Shaunik, A. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000643 · Cited by 6
Morillas, C., Escalada, J., Palomares, R., Bellido, D., Peralta, F. G., & Pérez, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0671-x · Cited by 4
Recent progress of remission in type 2 diabetes
Zhao, Z., Yue, H., Zhang, X., Chen, F., Xu, J., & Shao, S. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251408210 · Cited by 4
Metabolic-Bariatric Surgery for Type 2 Diabetes: Time(ing) for a Change
Purnell, J. Q. (2024) · Diabetes · doi:10.2337/dbi23-0022 · Cited by 3
Glucagon-like Peptide 1 and Type 2 Diabetes: Targets and New Therapies
Sheikhpour, R. (2012) · Indian Journal of Science and Technology · doi:10.17485/ijst/2012/v5i6/30482 · Cited by 3
“prandial GLP-1 levels (2) reduces fasting and prandial glucose (3) improves islet β and α-cell function in T2DM (4) increases β-cell mass (5) increases insulin sensitivity”
BackgroundYang, L., Han, M.-M., He, Q., Liu, Z., Liang, D., Hou, J.-T., Zhang, Y., & Liu, Y. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i12.654 · Cited by 3
COMPARATIVE STUDY REGARDING COMMERCIAL POLICIES FOR THE ROMANIAN ANTIDIABETICS' MARKET
Morgovan, C., COSMA, S. A., & Ghibu, S. (2011) · Cited by 3
Quo vadisnateglinide? Ten-year perspective
Grunberger, G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.600305 · Cited by 3
Targeting Obesity for the Treatment of Type 2 Diabetes Mellitus
Feng, D. Z. Y. (2014) · Journal of Cytology & Histology · doi:10.4172/2157-7099.1000215 · Cited by 2
Traitement du diabète en dehors de l'insuline
Blickle, J. (2011) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(11)48522-x · Cited by 3
Incretin Therapy and Beta Cell Function
Goundan, P. N., UNDERWOOD, P. C., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.006 · Cited by 2
Glucagon-like peptide-1 agonists for weight loss in people with obesity
Kirk, S., Shamliyan, T., & Middleton, M. (2017) · Obesity Medicine · doi:10.1016/j.obmed.2017.01.003 · Cited by 2
Ehrhardt, N. M., Fazeli, S., Rao, S., & AMDUR, R. L. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0025 · Cited by 3
Brown, L. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-73317-9_25-1 · Cited by 2
Skyler, J. S. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1028-7_18 · Cited by 2
Palumbo, P. J., & Wert, J. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s8564 · Cited by 2
What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms
Freeman, J. S., & Horton, E. S. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31826fc5e5 · Cited by 2
Guerci, B., Halimi, S., Gourdy, P., & Disse, E. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70330-3 · Cited by 2
Hribal, M. L., & Sesti, G. (2011) · Clinical Investigation · doi:10.4155/cli.10.26 · Cited by 2
Diabetic gastroparesis: Therapeutic options
Alam, U., Asghar, O., & Malik, R. A. (2010) · Diabetes Therapy · doi:10.1007/s13300-010-002-82010 · Cited by 2
Odegard, P. S., & DeSantis, A. J. (2009) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s4444 · Cited by 3
Miyagi, M., Uchino, H., Kumashiro, N., Higa, M., Shin, K., Sasamoto, M., Kitazato, H., Tamaki, M., Matsuhisa, M., & Hirose, T. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0486-1 · Cited by 2
Combination therapy in type 2 diabetes mellitus
Abdul‐Ghani, M. A., DeFronzo, R. A., & Eldor, R. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch46 · Cited by 3
VersorgungsLeitlinie, N. (2011) · Cited by 2
Bai, S., Lin, C., Jiao, R., Cai, X., Hu, S., Lv, F., Yang, W., Zhu, X., & Ji, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.01.008 · Cited by 2
Ning, X., Munir, K. M., & Davis, S. N. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2439501 · Cited by 2
“This is in line with studies done in T2DM where after 1 year of therapy with exenatide, beta cell function returned to pre-treatment values after a 4-week drug off period [34].”
Beta-cell preservation in T2DM using a pathophysiologic approach
Papatheodorou, K., & Shubrook, J. H. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2494502 · Cited by 3
“A one-year study in which participants were treated with metformin and exenatide for 1 year showed significant improvement during the 52 weeks, but beta-cell function reverted to pretreatment values once the GLP-1 receptor agonist was discontinued [26].”
Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives
Liu, Y., Gang, X., Liu, X., Jiang, W., Yang, Y., & Wang, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1687601 · Cited by 3
DPP‐4‐Inhibitoren in der Klinik. Therapie ohne Hypoglykämie‐Gefahr
Gallwitz, B. (2010) · Pharmazie in unserer Zeit · doi:10.1002/pauz.201000358 · Cited by 1
A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus
Samat, A., Bhargava, A., & Reddy, V. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s3489 · Cited by 2
Incretins: new targets for the prevention of diabetes and obesity
Neff, K., & le Roux, C. W. (2013) · Clinical Lipidology · doi:10.2217/clp.12.80 · Cited by 1
How Do Incretin-Based Therapies Fit Into the Treatment Algorithm?
Chia, S.-Y. (2011) · The Singapore Family Physician · Cited by 1
Pharmacology of the GLP-1 analog exenatide extended-release in healthy cats
Rudinsky, A. J. (2015) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Zin, Z. F. (2012) · Cited by 1
Fujitani, Y. (2012) · Juntendō Igaku/Juntendo igaku · doi:10.14789/pjmj.58.490 · Cited by 1
Brown, L. R. (2013) · Springer eBooks · doi:10.1007/978-3-642-25240-2_25 · Cited by 1
Bilous, F. R., & Donnelly, R. (2010) · doi:10.1002/9781444391374.ch11 · Cited by 1
Exenatide Response in an Adolescent’s Morbid Obesity
Sánchez, R. S., Ruiz, A. L., Núñez‐Sánchez, M. Á., Espin, N. V. G.-T., Aviles, A. M., García, M. T. G., Gilsanz, C. D. P., Palao, J. S., & Sofía, C. G. O. T. D. O. U. O. T. H. R. (2014) · Pharmacology & Pharmacy · doi:10.4236/pp.2014.54051
Is there a Role for Incretin‐Based Therapy in Combination with Insulin?
Sathananthan, M., & Vella, A. V. (2011) · Wiley eBooks · doi:10.1002/9781444340280.ch10
Gemeinsamkeiten und Unterschiede inkretinbasierter Therapien
Gallwitz, B. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0696-x · Cited by 1
Bories, T. (2012) · OpenGrey (Institut de l'Information Scientifique et Technique)
TRANSLATIONAL MEDICINE AND ITS IMPACT ON DIABETES DRUG DEVELOPMENT
Calle, R. A., & Taylor, A. E. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976087.004
Codario, R. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-441-8_8
Evidence review : liraglutide for the treatment of type 2 diabetes
Cummins, E., Royle, P., Shyangdan, D., & Waugh, N. R. (2011) · Warwick Research Archive Portal (University of Warwick) · doi:10.82444/warw.33664453 · Cited by 3
Juurinen, L. (2014) · Helda - University of Helsinki Institutional Repository
Traitement du diabète de type 2 : l’exénatide, en alternative ou en association à l’insuline ?
Guerci, B., & Sauvanet, J.-P. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70536-4
Can we prevent diabetes with a single pill?
Tripathy, D., & DeFronzo, R. A. (2011) · Diabetes Management · doi:10.2217/dmt.11.35
Morbid Obesity in Diabetes Mellitus Type 2 and Exenatide
Gil, M. Á. I., Ruiz, A. L., Torres, A. H., Cascales, A. B. H., Pujante, P., & Gil, M. D. H. (2014) · Pharmacology & Pharmacy · doi:10.4236/pp.2014.52020
Krentz, A. J., Heinemann, L., & Hompesch, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_2
“studied metformin-treated patients with type 2 diabetes randomly assigned to the GLP-1 analogue exenatide or insulin glargine titrated to target according to a prespecifi ed algorithm [ 115 ].”
BackgroundMethodMannucci, E. (2010) · Giornale italiano di cardiologia · doi:10.1714/565.6707
GLP‐1‐Mimetika in klinischen Studien. Therapie durch Aktivierung des GLP‐1‐Rezeptors
Ritzel, R. A. (2010) · Pharmazie in unserer Zeit · doi:10.1002/pauz.201000359
β-Zell-Erhalt durch inkretinbasierte Therapien: Fiktion oder Wirklichkeit?
Menge, B. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0700-5
Glucagon-like peptide-1 e sistema cardiovascolare: meccanismi fisiopatologici
Avogaro, A. (2010) · Giornale italiano di cardiologia · doi:10.1714/565.6706 · Cited by 2
Review Article Advances in pharmacotherapy of Type-2 diabetes (Part-2: The incretin mimetics)
Elhadd, T. A., Ghosh, S. K., Mrcp, Ibrahim, I. M., & Ahmed, A. B. (2009)
- Self-citation
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., & Costi, B. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_30
Bayón, C., Araceli, B. M., & de León, L. F.-D. (2010)
ApproachtoTherap y in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., & Eldor, R. (2013)
Incretins, Incretinmimetics, Inhibitors (2 nd part)
Bayón, C., Araceli, B. M., & de León, L. F.-D. (2010)
Analoghi del glucagon-like peptide-1: effetti su glicemia e peso corporeo
Ruffo, M., Hribal, M. L., & Sesti, G. (2010) · Giornale italiano di cardiologia · doi:10.1714/565.6705
The Effect of Exenatide Therapy in Previously Insulin-Treated Type 2 Diabetic Patients
Yasar, H., Ceyhan, B. O., Pamuk, B. O., Demirpence, M., Ertugrul, O., & Ertugrul, D. (2017) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2017.447
“Type 2 diabetes is characterized by progressive loss of beta-cell function and insulin resistance (1, 2).”
BackgroundInfluentialClinical and basic studies of GLP-1 receptor agonists for the treatment of diabetes in China
Hong, T., Liu, J., & Wei, R. (2018) · Scientia Sinica Vitae · doi:10.1360/n052018-00030 · Cited by 1
Esmail, S., Banzal, S., & Kabadi, U. M. (2018) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2018.84015
“84015 156 Journal of Diabetes Mellitus glucagon release is well established [2]-[7].”
BackgroundDevelopment of disease progression model in korean patients with type 2 diabetes mellitus
이동환 (2013) · YUHSpace (Yonsei University Medical Library)
Glucotoxicité et lipotoxicité dans le diabète de type 2 : comment protéger la cellule β ?
Scheen, A. J. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.05.005
Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor
Chilton, A. (2015)
Identification of a Dual-Action Small Molecule with Potent Anti-diabetic and Anti-obesity Activity
Wang, Y. (2019) · VTechWorks (Virginia Tech)
Antidiabetika: Gewichtsreduktion als wünschenswerter Begleiteffekt
Wirth, A. G. (2011) · Der Internist
Effect of Metformin Intervention on Pancreatic β-Cell Apoptosis
Xie, D., Gao, Z., Liu, M., & Wang, D. (2022) · Journal of Biomaterials and Tissue Engineering · doi:10.1166/jbt.2022.3013
Current literature in diabetes
(2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1037
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., Costi, B. B., & Cardoso, A. C. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_31
Utzschneider, K. M., Ehrmann, D. A., Arslanian, S. A., Barengolts, E., Buchanan, T. A., Caprio, S., Edelstein, S. L., Hannon, T. S., Kahn, S. E., Kozedub, A., et al. (2022) · Obesity · doi:10.1002/oby.23475
Shi, L., Meng, S., & Ruan, Y. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.4.13
Ling, W., Wang, Y.-C., Huang, Y., Ou, Y.-X., & Jiang, Y. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.94976 · Cited by 1
Ganakumar, V., Fernandez, C. J., & Pappachan, J. M. (2026) · World Journal of Diabetes · doi:10.4239/wjd.116477
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Alsmadi, M. M., & Obaidat, R. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03489-1
Metadata
- Authors
- Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Heine, R. J.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Department of Endocrinology, Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands;
- Helsinki University Hospital (FI)
- Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Göteborg, Sweden;
- Amylin Pharmaceuticals, San Diego, California;
- Eli Lilly (Netherlands) (NL)
- Sahlgrenska University Hospital (SE)
- Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland;
- Eli Lilly (United States) (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-02-05
- Volume
- 32
- Issue
- 5
- Pages
- 762-768
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2671094
- OpenAlex
- W2148798434
- Cited by
- 388
- References
- 27
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 7 · 2021: 5 · 2020: 8 · 2019: 12 · 2018: 8 · 2017: 16 · 2016: 19 · 2015: 24 · 2014: 34 · 2013: 40 · 2012: 44
- FWCI
- 46.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, insulin glargine, type 2 diabetes, beta-cell function, metformin, glycemic control, HbA1c, body weight, C-peptide secretion, drug discontinuation, GLP-1 receptor agonists
- MeSH terms
- Insulin Glargine, Exenatide, Insulin Secretion, Arginine, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Kinetics, Male, Metformin, Middle Aged, Peptides, Venoms, Body Mass Index, Insulin, Long-Acting, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.